Status:
COMPLETED
Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Depressive Disorder, Major
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The primary purpose of this study is to examine whether IV hydrocortisone can speed up the time required for Venlafaxine XR to work.
Detailed Description
Participants will be treated with Venlafaxine XR for 6 weeks. The dose of Venlafaxine XR will begin at 37.5 mg/day and be gradually increased to a maximum of 225 mg/day. The dose may be kept as low as...
Eligibility Criteria
Inclusion
- :- outpatients at least 18 years of age
- current major depressive episode
- HDRS greater than or equal to 21
- good physical health
Exclusion
- history of sensitivity, intolerance, or non-response to venlafaxine
- history of sensitivity to hydrocortisone
- history of bipolar 1 illness
- meets DSM-IV criteria for a current or past psychotic disorder
- meets DSM-IV criteria for substance abuse or dependence in previous 6 months
- significant imminent suicide risk
- medical condition that would compromise participation in the study
- woman of child bearing potential not using adequate birth control in the opinion of the investigator
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00186264
Start Date
August 1 2002
End Date
April 1 2006
Last Update
October 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305